This is the first study to demonstrate that young women treated with RT for HL have an increased risk of developing ER-positive/PR-positive and ER-negative/PR-negative BC compared with expected values in an age-matched series of BC in the general population. The gene discussed is PGR; the disease is Hodgkins lymphoma.